Withdrawals due to adverse events · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Short‐term overall improvement (three months or less) · patients with CTS
Therapeutic ultrasound may leads to higher short‐term overall improvement (three months or less) compared with placebo (low certainty).
1 finding from 1 review
Adverse effects · patients with CTS
1 finding from 1 review
Short‐term improvement in pain and/or paraesthesia (after seven weeks of treatment) Scale from: zero to 10 · patients with CTS
1 finding from 1 review
Change in grip strength · patients with CTS
1 finding from 1 review
Long‐term improvement in CTS symptoms (number of participants with complete remission of subjective symptoms) (six months · patients with CTS
Therapeutic ultrasound may leads to higher long‐term improvement in CTS symptoms (number of participants with… compared with placebo (low certainty).
1 finding from 1 review
Long‐term improvement in pain and/or paraesthesia (six months · patients with CTS
1 finding from 1 review
Long‐term improvement in hand grip strength (six months · patients with CTS
1 finding from 1 review
Intervention not reported
Mortality or tracheostomy at 12 months (pooled hazard ratio)(riluzole 100 mg) · patients with ALS/MND
The intervention showed no clear difference in mortality or tracheostomy at 12 months (pooled hazard… (high certainty).
1 finding from 1 review
Intervention not reported
Per cent mortality at 12 months (riluzole 100 mg) · patients with ALS/MND
The intervention leads to lower per cent mortality at 12 months (riluzole 100 mg) (high certainty).
1 finding from 1 review
Intervention not reported
Rate of decline of Norris Scale ‐ Norris Limb (riluzole 100 mg) · patients with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of Norris Scale ‐ Norris Bulbar (riluzole 100 mg) · patients with ALS/MND
1 finding from 1 review
Intervention not reported
Adverse event: nausea · patients with ALS/MND
The intervention leads to higher adverse event: nausea (high certainty).
1 finding from 1 review
Intervention not reported
Adverse event: asthenia · patients with ALS/MND
The intervention leads to higher adverse event: asthenia (high certainty).
1 finding from 1 review
Intervention not reported
Adverse event: 3‐fold increase in alanine transferase · patients with ALS/MND
The intervention leads to higher adverse event: 3‐fold increase in alanine transferase (high certainty).
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ change in AALSRS at 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ change in SIP after 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
no estimate extracted
156 participants
Low
Intervention not reported
rhIGF‐I, all doses ‐ injection site pain · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, all doses ‐ injection site inflammation/reaction · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review